EUVIMEDEUVIMED entdecken
Crossref

Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML

Lindsey G DeRatt iD, Zhuming Zhang iD, Christine Pietsch, Justin S Cisar iD, Xiaochun Zhang, Weixue Wang, Alexandra Tanner, Rosalie Matico, Paul Shaffer, Edgar Jacoby, Faraz Kazmi, Neetu Shukla und 6 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00809 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Lindsey G DeRatt und 17 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Research and Development, Spring House, Pennsylvania 19477, United States. Hauptthemen laut MEDLINE: Dihydroorotate Dehydrogenase, Oxidoreductases Acting on CH-CH Group Donors, Leukemia, Myeloid, Acute, Enzyme Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myelogenous leukemia (AML), a heterogeneous disease of the blood and bone marrow, is characterized by the inability of myeloblasts to differentiate into mature cell types. Dihydroorotate dehydrogenase (DHODH) is an enzyme well-known in the pyrimidine biosynthesis pathway and preclinical findings demonstrated that DHODH is a metabolic vulnerability in AML as inhibitors can induce differentiation across multiple AML subtypes. As a result of virtual screening and structure-based drug design approaches, a novel series of isoquinolinone DHODH inhibitors was identified. Further lead optimization afforded JNJ-74856665 as an orally bioavailable, potent, and selective DHODH inhibitor with favorable physicochemical properties selected for clinical development in patients with AML and myelodysplastic syndromes (MDS).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydroorotate DehydrogenaseOxidoreductases Acting on CH-CH Group DonorsLeukemia, Myeloid, AcuteEnzyme InhibitorsHumansAnimalsStructure-Activity RelationshipDrug DiscoveryRatsAntineoplastic AgentsQuinolonesCell Line, TumorMolecular Docking Simulation

Substanzen

Dihydroorotate DehydrogenaseOxidoreductases Acting on CH-CH Group DonorsEnzyme InhibitorsAntineoplastic AgentsQuinolones

Autor:innen und Institutionen

  • Janssen Research and Development, Spring House, Pennsylvania 19477, United States.
  • Janssen Research and Development, Turnhoutseweg 30, B-2340 Beerse, Belgium.

ORCID-Profile: Lindsey G DeRatt, Zhuming Zhang, Justin S Cisar

Zitieren

APA

DeRatt, L. G., Zhang, Z., Pietsch, C., Cisar, J. S., Zhang, X., Wang, W., Tanner, A., Matico, R., Shaffer, P., Jacoby, E., Kazmi, F., Shukla, N., Bush, T. L., Patrick, A., Philippar, U., Attar, R., Edwards, J. P., & Kuduk, S. D. (2024). Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00809

Vancouver

DeRatt LG, Zhang Z, Pietsch C, Cisar JS, Zhang X, Wang W, et al. Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00809

BibTeX
@article{DeRatt2024,
  author = {DeRatt, Lindsey G and Zhang, Zhuming and Pietsch, Christine and Cisar, Justin S and Zhang, Xiaochun and Wang, Weixue and Tanner, Alexandra and Matico, Rosalie and Shaffer, Paul and Jacoby, Edgar and Kazmi, Faraz and Shukla, Neetu and Bush, Tammy L and Patrick, Aaron and Philippar, Ulrike and Attar, Ricardo and Edwards, James P and Kuduk, Scott D},
  title = {Discovery of JNJ-74856665: A Novel Isoquinolinone DHODH Inhibitor for the Treatment of AML},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00809}
}
Kostenlos starten →